Head to head
Penumbra vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: PEN · ABT
PEN
Penumbra
316.35-0.22%
1-year price shape — +27% over the period
Quant Rating D · 65/100
vs
ABT
Abbott Laboratories
98.73+0.58%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories trades cheapest on trailing earnings; Abbott Laboratories pays the highest dividend yield.
| PEN | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 316.35 | 98.73 |
| Change today | -0.22% | +0.58% |
| 1-year return | +27.0% | -24.1% |
| Market cap | $12.46B | $170.84B |
| 52-week range | 221.26 – 362.41 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | 77.73 | 31.95 |
| P/E percentile, own 5-yr range | 40th | 62nd |
| P/B | 8.14 | 3.34 |
| Dividend yield | 0.00% | 2.47% |
| Profitability & growth | ||
| EPS (TTM) | 4.52 | 3.72 |
| Net profit (TTM) | $178.04M | $6.44B |
| Revenue (TTM) | $1.50B | $46.59B |
| Revenue growth (YoY) | +14.9% | +13.0% |
| Gross margin | 67.8% | 56.6% |
| Operating margin | 12.4% | 15.8% |
| Net margin | 10.7% | 11.6% |
| Free cash flow (TTM) | $215.91M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 88.0% | 81.2% |
| Insider activity (12mo) | 14 buy / 36 sell | 36 buy / 12 sell |
| Short interest (% of float) | 4.6% | 1.1% |
| Analyst consensus | 17% buy / 83% hold (6) | 100% buy (14) |
| Analyst price target | $358 (+13%) | $125 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | D (65) | E (15) |
| Company | ||
| Employees | 4,700 | 115,000 |
| Founded | 2004 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.